Skip to content

Microbiota and Allergy

Microbiota as Potential Target for Innovative Preventive and Therapeutic Strategies for Food Allergy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04750980
Acronym
MATFA I
Enrollment
120
Registered
2021-02-11
Start date
2017-06-01
Completion date
2021-01-30
Last updated
2021-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Brief summary

Food allergy derives from a dysregulation of oral tolerance mechanisms. Studies suggest a crucial role for gut microbiota in oral tolerance development. An altered composition of gut microbiota results in an unbalanced local and systemic immune response to food allergens. There are qualitative and quantitative differences in gut microbiota composition in children with food allergy. Preliminary results of MATFA study demonstrated gut microbiota in allergic children.These findings support the pivotal role of the gut microbiota in the pathogenesis of allergic diseases and may open new strategies in the development of innovative preventive and therapeutic approaches.

Interventions

OTHERfood allergy

food allergy

OTHERrespiratory allergy

respiratory allergy

OTHERhealthy controls

healthy controls

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
48 Months to 84 Months

Inclusion criteria

* Children with sure diagnosis of food allergy, * children with sure diagnosis of respiratory allergy

Exclusion criteria

* age at enrollment \<48 months or \>84 months; * eosinophilic disorders of the gastrointestinal tract; * chronic systemic diseases; * congenital cardiac defects; * acute or chronic infections; * autoimmune diseases; * immunodeficiencies; * chronic inflammatory bowel diseases; * celiac disease; * cystic fibrosis or other forms of primary pancreatic insufficiency; * genetic and metabolic diseases; * food intolerances; * malignancy; * chronic pulmonary diseases; * malformations of the respiratory tract or of the gastrointestinal tract; * pre-, pro- or sinbiotic use in the previous 3 months; * antibiotics or gastric acidity inhibitors use in the previous 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of gut microbiome features in allergic children and in healthy controls.at enrollmentComparatively evaluation of gut microbiome features in allegic children and in healthy controls.

Secondary

MeasureTime frameDescription
Gut microbiome and allergy disease courseat enrollmentEvaluation of gut microbiome influence on allergy disease course
Evaluation of gut microbiome features in children affected by different allergies (food and respiratory)at enrollmentComparatively evaluation of gut microbiome features in children with different allergies (food and respiratory)
Evaluation of gut microbiome features in children affected by different type of food allergyat enrollmentEvaluation of gut microbiome features in children affected by different type of food allergy

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026